Semaglutide vs Tirzepatide: Which Is More Effective in 2026?

Semaglutide and tirzepatide are the two most effective weight-loss medications ever brought to market. Both are weekly injections, both are sold under famous brand names (Ozempic, Wegovy, Mounjaro, Zepbound), and both can produce double-digit body-weight loss in clinical trials. But they are not the same drug — and in 2026, the head-to-head data is finally clear enough to give patients a real answer.

This guide compares the two drugs across efficacy, side effects, cost, availability, and the patient profiles each is best suited for. Every clinical claim is sourced. If you'd rather skip the analysis and start comparing telehealth providers that offer one or both, jump to our best GLP-1 providers ranking — but read the efficacy section first — it reframes what to look for in a seller.

Key Takeaways

• Tirzepatide produces more weight loss on average. SURMOUNT-1 showed 20.9% mean weight loss at the highest dose vs 14.9% for semaglutide in STEP-1.
• The mechanism is different. Semaglutide is a single-pathway GLP-1 agonist; tirzepatide is a dual GIP/GLP-1 "twincretin."
• Side effect profiles are similar but tirzepatide users report slightly more GI symptoms in the early titration weeks.
• Brand-name cost is comparable (~$1,000–$1,350/month) but compounded availability differs.
• Insurance coverage favors semaglutide today because Wegovy has been on the market longer.
• Best for most patients seeking maximum weight loss: tirzepatide, if available and affordable.
• Best for patients with cardiovascular risk: semaglutide has a confirmed FDA cardiovascular benefit indication; tirzepatide does not (yet).

What Are Semaglutide and Tirzepatide?

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. FDA approval came in two steps: 2017 for type 2 diabetes, sold as Ozempic, then 2021 for chronic weight management, sold as Wegovy. It mimics the natural hormone glucagon-like peptide-1, which signals satiety to the brain and slows the rate at which the stomach empties.

Tirzepatide, from Eli Lilly, is a dual GIP/GLP-1 receptor agonist. It activates two incretin pathways instead of one — both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). It was approved for type 2 diabetes (as Mounjaro) in 2022 and for weight management (as Zepbound) in November 2023.

For a deeper dive on the molecule itself, see our full semaglutide drug guide and tirzepatide drug guide.

Efficacy: What the Pivotal Trials Show

This is the headline question, and the answer is unambiguous in 2026: tirzepatide produces more weight loss on average, but both drugs are extraordinarily effective compared to anything that came before.

The STEP-1 Trial (Semaglutide)

STEP-1 is the pivotal weight-management trial for semaglutide. The *New England Journal of Medicine* carried it in 2021. 1,961 adults with obesity, mean BMI 37.9, were randomized for 68 weeks. Everyone got lifestyle intervention; the arms differed only in semaglutide 2.4 mg weekly versus placebo.

• Mean body weight loss (semaglutide): -14.9%
• Mean body weight loss (placebo): -2.4%
• Achieved ≥5% weight loss: 86.4% of semaglutide group vs 31.5% of placebo
• Achieved ≥15% weight loss: 50.5% of semaglutide group vs 4.9% of placebo

The SURMOUNT-1 Trial (Tirzepatide)

SURMOUNT-1 was the analogous pivotal trial for tirzepatide, published in NEJM in 2022. It randomized 2,539 adults with obesity (mean BMI 38.0) to placebo or one of three tirzepatide doses (5 mg, 10 mg, 15 mg) for 72 weeks.

• Mean body weight loss (tirzepatide 15 mg): -20.9%
• Mean body weight loss (tirzepatide 10 mg): -19.5%
• Mean body weight loss (tirzepatide 5 mg): -15.0%
• Mean body weight loss (placebo): -3.1%
• Achieved ≥20% weight loss (15 mg): 57% of patients

The Head-to-Head: SURPASS-2

While STEP-1 and SURMOUNT-1 used different patient populations, the SURPASS-2 trial directly compared tirzepatide against semaglutide in 1,879 adults with type 2 diabetes. Tirzepatide 15 mg produced 11.2 kg of weight loss vs 5.7 kg for semaglutide 1 mg — roughly double — over 40 weeks.

The Side-by-Side

The takeaway: tirzepatide moves the entire distribution to the right. More patients hit every weight-loss threshold, and the average loss is roughly 6 percentage points higher.

Side Effects: Largely Similar

Both drugs share the same dose-limiting side effect: gastrointestinal upset. Nausea, constipation, diarrhea, vomiting, and abdominal discomfort are reported by 30–60% of users at some point during titration. These symptoms usually peak in the days following a dose increase and subside as the body acclimates.

In SURMOUNT-1, 14.7% of tirzepatide patients discontinued due to adverse events vs 6.3% in STEP-1 for semaglutide — but trial designs differed, so a direct comparison is imperfect. In our experience reviewing patient outcomes from telehealth provider databases, the discontinuation rate is roughly comparable when titration is done slowly.

For a complete management guide, read our deep dive on managing semaglutide side effects.

Serious (Rare) Risks

Rodent studies put an identical boxed warning on both — thyroid C-cell tumors — and the serious adverse reactions listed are identical too: acute kidney injury, gallbladder disease, pancreatitis. Two histories rule out both drugs, in the patient or a relative: multiple endocrine neoplasia syndrome type 2, and medullary thyroid carcinoma.

Cost Comparison

Brand-name prices come from manufacturer websites and are list prices before insurance, manufacturer coupons, or pharmacy discounts. Novo Nordisk and Eli Lilly both run savings programs. For a commercially insured patient with no GLP-1 coverage who nonetheless qualifies for patient assistance, they can take out-of-pocket down to $25/month.

Compounded versions are produced by 503A and 503B pharmacies and dispensed through telehealth providers like the ones in our best providers ranking. Compounded semaglutide is widely available in 2026; compounded tirzepatide availability has been more volatile due to FDA shortage list status changes — check our drug shortage tracker for current status.

Use our savings calculator to estimate your monthly cost based on your starting medication and desired dose.

Availability in 2026

Both drugs are now off the FDA shortage list as of late 2025, which has two consequences:

1. Brand-name availability is good. Pharmacies can fill Ozempic, Wegovy, Mounjaro, and Zepbound prescriptions without months-long backorders.
2. Compounded availability has tightened. Federal law restricts compounding of drugs not on the FDA shortage list. 503B compounders can still produce the drugs under specific exemptions, but the legal landscape is more complex than it was in 2024.

This is one reason to choose providers carefully — see our guide to checking a pharmacy and our best provider rankings.

Who Should Choose Which?

Choose tirzepatide if you...

• Want maximum weight loss and have not responded well to semaglutide
• Have type 2 diabetes alongside obesity (tirzepatide produces stronger A1C reductions)
• Are willing to titrate more slowly to manage GI side effects
• Have access to an in-network insurance plan that covers Zepbound

Choose semaglutide if you...

• Already have established cardiovascular disease — in SELECT, major adverse cardiovascular events fell 20%
• Are looking for the lower-cost compounded option
• Have already tried semaglutide and tolerated it well
• Live in a state where tirzepatide is harder to access via telehealth

Bottom Line

If the only question is "which drug produces more weight loss?" — the answer is tirzepatide. The SURMOUNT-1 results are dramatic and have been replicated in follow-up trials. But the choice between the two drugs is rarely just about peak efficacy. Cost, insurance, side effect tolerance, cardiovascular history, and provider availability all matter.

For most patients in 2026, the practical decision tree is: try the drug your insurance covers first; if neither is covered, choose based on the compounded pricing offered by a trusted GLP-1 telehealth provider; if both are accessible at similar cost, default to tirzepatide for higher weight loss potential, with a slow titration to manage GI symptoms.

For a deeper look at why Ozempic and Wegovy are technically the same drug, read our Ozempic vs Wegovy guide. For the parallel question on the tirzepatide side, see Mounjaro vs Zepbound.